These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 31550266)

  • 21. How effective is dose-intensive/myeloablative therapy against Ewing's sarcoma/primitive neuroectodermal tumor metastatic to bone or bone marrow? The Memorial Sloan-Kettering experience and a literature review.
    Kushner BH; Meyers PA
    J Clin Oncol; 2001 Feb; 19(3):870-80. PubMed ID: 11157041
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Successful Treatment of Patient With Ewing Sarcoma in the Setting of Inherited Cholestatic Liver Disease.
    Daley J; Halligan K; Howrie D; Salgado CM; Superdock A; Friehling E; Bailey KM
    J Pediatr Hematol Oncol; 2023 Jul; 45(5):e621-e623. PubMed ID: 36728269
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lysine-specific demethylase 1 (LSD1/KDM1A/AOF2/BHC110) is expressed and is an epigenetic drug target in chondrosarcoma, Ewing's sarcoma, osteosarcoma, and rhabdomyosarcoma.
    Bennani-Baiti IM; Machado I; Llombart-Bosch A; Kovar H
    Hum Pathol; 2012 Aug; 43(8):1300-7. PubMed ID: 22245111
    [TBL] [Abstract][Full Text] [Related]  

  • 24. SP2509, a Selective Inhibitor of LSD1, Suppresses Retinoblastoma Growth by Downregulating β-catenin Signaling.
    Jiang A; Wu W; Xu C; Mao L; Ao S; Guo H; Sun X; Tao J; Sang Y; Huang G
    Invest Ophthalmol Vis Sci; 2022 Mar; 63(3):20. PubMed ID: 35297943
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cytotoxic effects of histone deacetylase inhibitor FK228 (depsipeptide, formally named FR901228) in combination with conventional anti-leukemia/lymphoma agents against human leukemia/lymphoma cell lines.
    Kano Y; Akutsu M; Tsunoda S; Izumi T; Kobayashi H; Mano H; Furukawa Y
    Invest New Drugs; 2007 Feb; 25(1):31-40. PubMed ID: 16865529
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Histone deacetylase inhibitors: a review on class-I specific inhibition.
    Behera J; Jayaprakash V; Sinha BN
    Mini Rev Med Chem; 2015; 15(9):731-50. PubMed ID: 25994050
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting epigenetic enzymes for autism treatment.
    Yan Z
    Trends Pharmacol Sci; 2024 Sep; 45(9):764-767. PubMed ID: 39034229
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current results with a combined treatment approach to localized Ewing's sarcoma.
    Gasparini M; Fossati-Bellani F; Bonadonna G
    Recent Results Cancer Res; 1978; 68():45-51. PubMed ID: 752881
    [No Abstract]   [Full Text] [Related]  

  • 29. BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma.
    Loganathan SN; Tang N; Fleming JT; Ma Y; Guo Y; Borinstein SC; Chiang C; Wang J
    Oncotarget; 2016 Jul; 7(28):43504-43517. PubMed ID: 27259270
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Effects of Combinatorial Genistein and Sulforaphane in Breast Tumor Inhibition: Role in Epigenetic Regulation.
    Paul B; Li Y; Tollefsbol TO
    Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29899271
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Schedule-dependent synergy of histone deacetylase inhibitors with DNA damaging agents in small cell lung cancer.
    Luchenko VL; Salcido CD; Zhang Y; Agama K; Komlodi-Pasztor E; Murphy RF; Giaccone G; Pommier Y; Bates SE; Varticovski L
    Cell Cycle; 2011 Sep; 10(18):3119-28. PubMed ID: 21900747
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Arsenic trioxide potentiates the effectiveness of etoposide in Ewing sarcomas.
    Boehme KA; Nitsch J; Riester R; Handgretinger R; Schleicher SB; Kluba T; Traub F
    Int J Oncol; 2016 Nov; 49(5):2135-2146. PubMed ID: 27665785
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Histone lysine demethylases as targets for anticancer therapy.
    Højfeldt JW; Agger K; Helin K
    Nat Rev Drug Discov; 2013 Dec; 12(12):917-30. PubMed ID: 24232376
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Functional, chemical genomic, and super-enhancer screening identify sensitivity to cyclin D1/CDK4 pathway inhibition in Ewing sarcoma.
    Kennedy AL; Vallurupalli M; Chen L; Crompton B; Cowley G; Vazquez F; Weir BA; Tsherniak A; Parasuraman S; Kim S; Alexe G; Stegmaier K
    Oncotarget; 2015 Oct; 6(30):30178-93. PubMed ID: 26337082
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Romidepsin induces cell cycle arrest, apoptosis, histone hyperacetylation and reduces matrix metalloproteinases 2 and 9 expression in bortezomib sensitized non-small cell lung cancer cells.
    Karthik S; Sankar R; Varunkumar K; Ravikumar V
    Biomed Pharmacother; 2014 Apr; 68(3):327-34. PubMed ID: 24485799
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design and synthesis of tranylcypromine derivatives as novel LSD1/HDACs dual inhibitors for cancer treatment.
    Duan YC; Ma YC; Qin WP; Ding LN; Zheng YC; Zhu YL; Zhai XY; Yang J; Ma CY; Guan YY
    Eur J Med Chem; 2017 Nov; 140():392-402. PubMed ID: 28987602
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Second malignancies after ewing tumor treatment in 690 patients from a cooperative German/Austrian/Dutch study.
    Paulussen M; Ahrens S; Lehnert M; Taeger D; Hense HW; Wagner A; Dunst J; Harms D; Reiter A; Henze G; Niemeyer C; Göbel U; Kremens B; Fölsch UR; Aulitzky WE; Voûte PA; Zoubek A; Jürgens H
    Ann Oncol; 2001 Nov; 12(11):1619-30. PubMed ID: 11822764
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combination of proteasome and class I HDAC inhibitors induces apoptosis of NPC cells through an HDAC6-independent ER stress-induced mechanism.
    Hui KF; Chiang AK
    Int J Cancer; 2014 Dec; 135(12):2950-61. PubMed ID: 24771510
    [TBL] [Abstract][Full Text] [Related]  

  • 39. LSD1 (KDM1A)-independent effects of the LSD1 inhibitor SP2509 in cancer cells.
    Sonnemann J; Zimmermann M; Marx C; Ebert F; Becker S; Lauterjung ML; Beck JF
    Br J Haematol; 2018 Nov; 183(3):494-497. PubMed ID: 29205263
    [No Abstract]   [Full Text] [Related]  

  • 40. [Progress in cancer treatment with histone deacetylase inhibitor].
    Dong M; Hu XS; Chen SS; Xing PY; Feng FY; Shi YK
    Zhonghua Zhong Liu Za Zhi; 2013 Jul; 35(7):481-5. PubMed ID: 24257296
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.